Efavirenz, also known as EFV or Sustiva, is a type of medicine called a non-nucleoside reverse transcriptase inhibitor (NNRTI). NNRTIs block reverse transcriptase, a protein that HIV needs to make more copies of itself. Efavirenz was approved by the FDA on September 17, 1998, for use with other antiretroviral agents in the treatment of HIV infection in adults and children ages 3 and older. This medicine does not cure HIV infection or AIDS and does not reduce the risk of passing the virus to other people. Efavirenz may also be used with other antiretroviral medications to prevent HIV in people who have been exposed to the virus in the work place, such as health care providers who come in contact with HIV infected blood through an accidental needle stick.
A study led by researchers at the Johns Hopkins Bloomberg School of Public Health found that HIV-infected patients taking the antiretroviral drug efavirenz were more likely to adhere to treatment and less likely to experience virologic failure and death compared to patients taking nevirapine.
Brazilian Health Minister Jose Gomes Temporao on Wednesday said Brazil will begin producing a generic version of Merck's antiretroviral efavirenz, the AP/USA Today reports.
A major study from a team of researchers from Weill Cornell Medical College and Massachusetts General Hospital has found that a recent change to HIV-treatment guidelines recommending genetic screening is cost-effective under certain conditions. The new recommendation suggests conducting a genetic screening test prior to prescribing the drug abacavir, one of the preferred first-line drugs for the treatment for HIV-infected adults.
Patients receiving rifampicin-based anti-tuberculosis therapy are more likely to experience virological failure when starting nevirapine-based antiretroviral therapy, an HIV treatment that is widely used in developing countries because of lower cost, than when starting efavirenz-based antiretroviral therapy, according to a study in the August 6 issue of JAMA, a theme issue on HIV/AIDS.
As more than 20,000 people from around the world gather this weekend for the start of the XVII International AIDS Conference in Mexico City, AIDS Healthcare Foundation (AHF) the US-based NGO which provides HIV/AIDS medical care and/or services to more than 79,000 individuals in 20 countries worldwide-including at four free treatment clinics in Mexico-commended Merck & Company (known as Merck, Sharp & Dohme in Mexico) over price cuts on two of its key AIDS drugs in Mexico which were announced yesterday before Sunday's opening of the AIDS conference.
Access to some antiretroviral drugs is increasing in Thailand because of the country's decision to issue compulsory licenses for certain medications, Winai Sawasdiworn, deputy secretary-general of the National Health Security Office, said recently, the Bangkok Post reports (Apiradee, Bangkok Post, 5/8).
Ardea Biosciences, Inc. has announced that it has successfully completed Phase 1 single-ascending-dose, multiple-ascending-dose, food-effect, and drug-interaction studies of RDEA806, a novel HIV non-nucleoside reverse transcriptase inhibitor (NNRTI), in healthy volunteers.
Democratic lawmakers and U.S. trade officials are in the final stages of negotiation over language to be added to international free trade agreements that would allow developing countries more flexibility in circumventing drug patents and other restrictions on pharmaceuticals, sources said recently, CongressDaily reports.
Bill Clinton has done deal with two generic drug companies which will ensure that developing countries will be able to access second line anti-retroviral AIDS drugs at reduced prices.
The Office of the U.S. Trade Representative in its annual report released on Monday placed Thailand on its Priority Watch List in part because the country recently issued compulsory licenses for several medicines, including two antiretroviral drugs, CongressDaily reports.
International health advocates and drug industry representatives are lobbying U.S. lawmakers and the Bush administration for their support in the dispute over Thailand's decision to issue compulsory licenses for medications, including some antiretroviral drugs, CongressDaily reports (Vaughan, CongressDaily , 4/26).
Brazilian Health Minister Jose Gomes Temporao on Wednesday signed a decree declaring that the country would purchase from an India-based drug maker a generic version of Merck 's antiretroviral Efavirenz if the company does not offer the drug at a lower price, the AP/Forbes reports.
The military government in Thailand has won the second round in it's battle to access cheaper AIDS drugs for the nations 580,000 AIDS sufferers.
Thailand's minister for health has reportedly threatened to override international patents on even more drugs if the big pharmaceutical manufacturers do not significantly cut their prices.
The United States Pharmacopeia (USP) has released free documentary standards for medicines used outside the United States to treat neglected infectious diseases.
Thailand's Ministry Of Public Health on Wednesday announced plans to issue a compulsory license to produce a lower-cost version of Merck's antiretroviral drug Efavirenz, Reuters reports.
Bristol-Myers Squibb on Friday announced that it has received FDA approval for a single 300 mg capsule formulation of its protease inhibitor Reyataz to be taken as part of combination therapy, Reuters reports.
Bristol-Myers Squibb Company and Gilead Sciences have announced the U.S. Food and Drug Administration (FDA) has granted approval of Atripla (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) for the treatment of HIV-1 infection in adults.
FDA approves Atripla Tablets, a fixed-dose combination of three widely-used antiretroviral drugs.
Former U.S. President Bill Clinton has struck a deal with nine drug companies to reduce the cost of the second-line AIDS drugs.